Sangamo Therapeutics agrees to sell gene therapy asset to PTC for $111 million

What happened

Sangamo Therapeutics, Inc., a Richmond, California-based biopharmaceutical company, announced on August 28, 2026, that it has entered into an asset purchase agreement with PTC Therapeutics, Inc. to sell all rights to its lead gene therapy candidate, ST-920 (isaralgagene civaparvovec), a one-time treatment for Fabry disease.

Under the agreement, PTC will pay $111 million in cash at closing, plus up to $100 million in milestone payments tied to FDA approvals. The sale is part of Sangamo's Chapter 11 bankruptcy proceedings, which began on June 23, 2026.

Sangamo's common stock was delisted from Nasdaq on May 5, 2026, and now trades on the OTC market under the symbol SGMOQ. The stock closed at $0.15 on the announcement date, unchanged from the prior close.

The bankruptcy context

Sangamo filed for Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The case is styled In re Sangamo Therapeutics, Inc., case number 26-10989.

On August 12, 2026, the company said it had completed a court-supervised auction of certain assets, and PTC was selected as the winning bidder. The asset purchase agreement was signed on August 25, 2026.

The sale is still subject to approval by the Bankruptcy Court. A hearing is scheduled for September 10, 2026. The agreement may be terminated if the sale does not close by October 15, 2026, unless extended.

What this means

An 8-K is a current report that companies must file with the SEC to announce major events, such as a material agreement or a bankruptcy proceeding. Here, the 8-K combines both, reporting the asset sale and the ongoing Chapter 11 case.

The asset being sold is ST-920, an investigational gene therapy for Fabry disease, a rare genetic disorder. The therapy uses a modified virus (AAV) to deliver a working copy of a gene to the body. This is a type of one-time treatment, so it is a product candidate, not yet approved by the FDA.

The milestone payments are contingent on regulatory success: $80 million if the FDA grants accelerated approval of a Biologics License Application (BLA) based on the Phase 1/2 STAAR study, and $20 million if full approval is granted. This structure is common in biotech deals, where the buyer pays upfront and pays more if the drug reaches certain goals.

The sale is proceeding under Section 363 of the Bankruptcy Code, which allows a company to sell assets during bankruptcy with court approval. The court must approve the sale order for the transaction to close.

For shareholders, the outcome is uncertain. In Chapter 11, common stock often becomes worthless, but the filing does not state that this will happen. The company's stock is still trading over-the-counter, but its value is speculative.